ClearPoint Neuro, Inc. Revenue Disclosure
4. Revenue Recognition
Revenue by Service Line
|
|
Year Ended December 31, |
|
|||||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Biologics and drug delivery |
|
|
|
|
|
|
||
Disposable products |
|
$ |
7,338 |
|
|
$ |
5,606 |
|
Services and license fees |
|
|
11,702 |
|
|
|
11,704 |
|
Subtotal – Biologics and drug delivery revenue |
|
|
19,040 |
|
|
|
17,310 |
|
Neurosurgery navigation and therapy |
|
|
|
|
|
|
||
Disposable products |
|
|
14,831 |
|
|
|
10,285 |
|
Subtotal – Neurosurgery navigation and therapy revenue |
|
|
14,831 |
|
|
|
10,285 |
|
Capital equipment and software |
|
|
|
|
|
|
||
Systems and software products |
|
|
1,690 |
|
|
|
2,735 |
|
Services |
|
|
1,410 |
|
|
|
1,060 |
|
Subtotal – Capital equipment and software revenue |
|
|
3,100 |
|
|
|
3,795 |
|
Total revenue |
|
$ |
36,971 |
|
|
$ |
31,390 |
|
Contract Balances
(in thousands) |
|
December 31, 2025 |
|
|
December 31, 2024 |
|
|
December 31, 2023 |
|
|||
Accounts receivable, net |
|
$ |
6,549 |
|
|
$ |
4,713 |
|
|
$ |
3,211 |
|
Other contract assets |
|
|
|
|
|
|
|
|
|
|||
Unbilled receivables |
|
$ |
714 |
|
|
$ |
642 |
|
|
$ |
733 |
|
Deferred contract costs |
|
$ |
150 |
|
|
$ |
— |
|
|
$ |
— |
|
(in thousands) |
|
December 31, 2025 |
|
|
December 31, 2024 |
|
|
December 31, 2023 |
|
|||
Contract liabilities |
|
$ |
2,250 |
|
|
$ |
2,557 |
|
|
$ |
3,154 |
|
During the years ended December 31, 2025 and 2024, the Company recognized capital equipment and software-related service revenue of approximately $2.1 million and $2.3 million, respectively, which was previously included in contract liabilities in the accompanying consolidated balance sheets at December 31, 2024 and 2023, respectively.
Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue that will be recognized as revenue in future periods. The majority of the remaining performance obligations relate to capital equipment and software-related service agreements and the upfront payments discussed under the heading “Contract Balances” above, which amounted to approximately $2.1 million at December 31, 2025. The Company expects to recognize approximately 72% of this revenue over the next twelve months and the remainder thereafter.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 17, 2026 | Showing above |
| 2024 | Feb 26, 2025 | |
| 2023 | Mar 12, 2024 | |
| 2022 | Mar 1, 2023 | |
| 2021 | Mar 9, 2022 | |
| 2020 | Mar 22, 2021 | |
| 2019 | Mar 27, 2020 | |
| 2018 | Apr 1, 2019 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.